Walking Fish Therapeutics has made critical advances in developing a platform to harness B cells' capability to activate the immune system in the treatment of cancer, and to serve as in vivo protein factories that produce replacement proteins for deficiency diseases, regenerative proteins, and engineered antibodies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/14/21 | $50,000,000 | Series A |
Emerson Collective Illumina Ventures Quan Capital | undisclosed |
| 02/17/22 | $23,000,000 | Series A |
First Spark Ventures Northpond Ventures Terra Magnum Capital Partners | undisclosed |
